Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a booster for the immune system tame a Slow-Moving lung fungus?

NCT ID NCT05653193

Disease control Sponsor: Manchester University NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial tests whether adding interferon-gamma to standard antifungal medication can help people with chronic pulmonary aspergillosis, a progressive lung infection caused by the Aspergillus fungus. The study will include 50 adults starting antifungal treatment, who will be randomly assigned to receive either interferon-gamma injections for 12 weeks plus antifungals, or antifungals alone. Researchers will measure changes in lung cavities on CT scans, quality of life, and how many patients complete the treatment, to see if a larger study is feasible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Interferon gamma-1b injection added to standard antifungal treatment
What this could lead to
If this approach works, it could shorten treatment duration, reduce relapses, and improve quality of life for people with chronic pulmonary aspergillosis.
What could go wrong
This is a small feasibility study, so results may not be conclusive. Interferon-gamma can cause side effects, and not all patients may tolerate or benefit from it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of CPA * Started antifungal treatment for CPA within the last 8 weeks and received no antifungals for CPA in the 8 weeks prior * Chest CT scan available within the 6 months prior to enrolment * Individuals of child bearing potential agree to have pregnancy test an use highly effective contraception Exclusion Criteria: * Moderate to severe liver dysfunction (Child-Pugh Class B or C) * Renal failure (eGFR \<30 mL/min) * Clinically diagnosed active depression * Active tuberculosis or non-tuberculous mycobacterial (NTM) lung disease * Acute infection or other event within the preceding 4 weeks which, as assessed by the investigators, might interfere with the assessment of response to treatment * Use of any interferon formulation within the preceding six months * Active viral hepatitis infection * Pregnancy or breastfeeding * Immunosuppression (\>15mg prednisolone/day for at least four weeks or equivalent) within the preceding six months * Inability to self-administer subcutaneous medications AND lack of a carer who can administer * Participants lacking capacity to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aspergillosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aspergillosis pulmonary aspergilloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aspergillosis Chronic pulmonary aspergillosis

Contacts and locations

Locations

  • Manchester University NHS Foundation Trust

    Manchester, M23 9LT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.